Temmune Therapeutics
The computed 12-month bankruptcy probability of Temmune Therapeutics is 1.2% (low). The 2025 annual accounts show equity of €2.01M and a net result of €-2.21M. The figures fluctuate too strongly year-on-year for a reliable trend projection. The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €2.01M |
| Net result | €-2.21M |
| Active | 4 yrs |
| Board | 6 |
Mixed profile: strong on solvency, weaker on profitability.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Fiscal year | 2025 |
|---|---|
| Deposit | verkort |
| Revenue | - |
| EBITDA | €-378k |
| Net profit | €-2.21M |
| Cash flow | €-322k |
| Staff costs | - |
| Income taxes | €-59k |
| Dividends | - |
| Total assets | €3.43M |
| Equity | €2.01M |
| Debt | €1.42M |
| of which ≤ 1y | €320k |
| of which > 1y | €1.10M |
| Working capital | €1.38M |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 5.30 |
| Quick ratio | 5.30 |
| Working capital ratio | 40.1% |
| Solvency | 58.6% |
| Debt / equity | 0.71 |
| Long-term debt ratio | 0.55 |
| Interest coverage | -52.17 |
| Gross margin | - |
| Net margin | - |
| ROA | -64.4% |
| ROE | -109.8% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | 57d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €3.43M |
| Fixed assets | 21/28 | €1.74M |
| Intangible fixed assets | 21 | €1.74M |
| Current assets | 29/58 | €1.70M |
| Amounts receivable within one year | 40/41 | €35k |
| Cash & bank | 54/58 | €1.46M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €3.43M |
| Equity | 10/15 | €2.01M |
| Contributions / capital | 10/11 | €4.35M |
| Accumulated profits (losses) | 14 | €-2.33M |
| Amounts payable | 17/49 | €1.42M |
| Amounts payable after one year | 17 | €1.10M |
| Amounts payable within one year | 42/48 | €320k |
| Trade debts payable within one year | 44 | €320k |
| Income statement | ||
| Gross operating margin | 9900 | €-377k |
| Operating result | 9901 | €-2.27M |
| Financial income | 75 | €4k |
| Financial charges | 65 | €7k |
| Result before taxes | 9903 | €-2.27M |
| Income taxes | 67/77 | €-59k |
| Net result for the period | 9904 | €-2.21M |
| Result to be appropriated | 9905 | €-2.21M |
-
Current07-04-2025 → present
-
LIFE of SCILegal entityDirector· perm. rep.: Joris De MaeyerState Gazette act 26040101 (20-03-2026)Current01-04-2025 → present
2 events
- 12-02-2026 Appointed· Director
- 01-04-2025 Appointed· Director
-
Current30-09-2024 → present
-
Current30-09-2024 → present
-
Current30-09-2024 → present
-
Current30-09-2024 → present
Former directors (2)
-
Former- → 01-04-2025
-
Bioqube Factory Project CompanyLegal entityDirector· perm. rep.: REYN DirkState Gazette act 24432220 (30-09-2024)Former- → 30-09-2024
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO Bedrijfsrevisoren bvCurrent Company auditor · represented by Gert Maris |
- | 23-09-2024 → present |
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISESCurrent Statutory auditor · represented by Gert Maris |
- | 30-09-2024 → present |
| NACE primary | Vervaardiging van geneesmiddelen(21201) |
| Legal form | Public limited company(014) |
| Incorporation | 08-11-2021 |
| Status | Active |
| Postal code | 2800 |
Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 12025C0760/00X000 | Flanders | 2,050 m² | 1 · 1,809 m² | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
20-03-2026 Joris De Maeyer appointed as director
- Joris De Maeyer, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Joris De Maeyer",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0563547828",
"name": "LIFE of SCI BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2026-02-12",
"evidence_quote": "De aandeelhouders gaan over tot de benoeming van de vennootschap LIFE of SCI BV, met zetel te Nonnenstraat 23, 2800 Mechelen, ingeschreven in Kruispuntbank van Ondernemingen onder nummer 0563.547.828 (RPR Antwerpen, afdeling Mechelen), vast vertegenwoordigd door dhr. Joris De Maeyer, als CEO bestuur"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0776.938.722",
"name_full": "TEMMUNE THERAPEUTICS, AFGEKORT : TEMMUNETX",
"legal_form": "NV"
}
}02-01-2026 2 directors appointed, 2 resigning
- HEYMAN Tom, Bestuurder
- WILMS Tobias, Bestuurder
- HEYMAN Tom, Bestuurder
- REYN Dirk, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "HEYMAN Tom",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "REYN Dirk",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "HEYMAN Tom",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "WILMS Tobias",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0776.938.722",
"name_full": "Temmune Therapeutics"
}
}30-06-2025 2 directors appointed, 1 resigning
- Tom Heyman, Bestuurder
- Joris De Maeyer, Bestuurder
- Andrew Lightfoot, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Andrew Lightfoot",
"address": null,
"birth_date": null
},
"effective_date": "2025-04-01",
"evidence_quote": "De aandeelhouders nemen hierbij kennis van en bekrachtigen het ontslag van dhr. Andrew Lightfoot, als bestuurder van de Vennootschap, met ingang vanaf 1 April 2025.",
"discharge_granted": true
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Tom Heyman",
"address": null,
"birth_date": null
},
"effective_date": "2025-04-07",
"evidence_quote": "De aandeelhouders gaan vervolgens over tot de benoeming van dhr. Tom Heyman, als bestuurder van de Vennootschap, met ingang vanaf 7 April 2025 voor een duurtijd van 6 jaar."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Joris De Maeyer",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0563547828",
"name": "LIFE of SCI",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2025-04-01",
"evidence_quote": "De raad van bestuur besluit eenparig om LIFE of SCI, een besloten vennootschap naar Belgisch recht, met zete! te nonnenstraat 23, 2800 Mechelen, ingeschreven in het Rechtspersonenregister bij de Kruispuntbank van Ondernemingen onder het nummer 0563.547.828 (RPR Antwerpen, afdeling Mechelen), vast ve"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0776.938.722",
"name_full": "TEMMUNE THERAPEUTICS, AFGEKORT : TEMMUNETX",
"legal_form": "NV"
}
}30-01-2025 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": true,
"object_change": true,
"effective_date": "2025-01-21",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0776.938.722",
"name_full": "TEMMUNE THERAPEUTICS, AFGEKORT : TEMMUNETX",
"legal_form": "NV"
},
"signature_regime": "joint_two",
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}30-09-2024 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2024-09-23",
"legal_form_change": true
},
"bedrijfsrevisor": {
"quote": "De conclusies van het verslag opgesteld door de bedrijfsrevisor, zijnde BDO Bedrijfsrevisoren, met zetel te Hasselt, vertegenwoordigd door Gert Maris, opgesteld op 23 september 2024, luiden letterlijk als volgt: ... Hasselt, 23 september 2024 BDO Bedrijfsrevisoren BV Vertegenwoordigd door Gert Maris Bedrijfsrevisor",
"firm_kbo": null,
"firm_name": "BDO Bedrijfsrevisoren BV",
"ibr_number": null,
"individual_name": "Gert Maris"
},
"subject_company": {
"kbo": "0776.938.722",
"name_full": "TEMMUNE THERAPEUTICS, AFGEKORT : TEMMUNETX",
"legal_form": "CommV"
},
"signature_regime": "joint_two",
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}05-03-2024 Registered office moved from Mechelen to Vosselaar
- Goswin de Stassartstraat 19, 2800 Mechelen → Roekendreef 14, 2350 Vosselaar
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Vosselaar",
"region": null,
"street": "Roekendreef",
"country": "BE",
"postcode": "2350",
"box_number": null,
"street_number": "14"
},
"old_address": {
"city": "Mechelen",
"region": null,
"street": "Goswin de Stassartstraat",
"country": "BE",
"postcode": "2800",
"box_number": null,
"street_number": "19"
},
"effective_date": "2023-08-31",
"evidence_quote": "Op 31 augustus 2023 heeft de Beheerder Bioqube Factory Project Company CommV, vertegenwoordigd door haar vaste vertegenwoordiger Dirk Reyn, beslist om de zetel van de Vennootschap met onmiddellijke ingang te verplaatsen naar de Roekendreef 14 te 2350 Vosselaar."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0776.938.722",
"name_full": "TEMMUNE THERAPEUTICS, AFGEKORT : TEMMUNETX",
"legal_form": "CommV"
}
}10-11-2021 Publication in the Belgian Official Gazette, Minor change
Technical details
{
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Luik",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2021-11-10",
"filing_date": "2021-11-08",
"act_kind_objet": "Oprichting"
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"date": "2021-10-29",
"unanimous": true
},
"agm_change": {
"new_schedule": "tweede vrijdag van de maand maart in 2023",
"old_schedule": null,
"effective_from_year": 2023,
"rule_changes_summary": null
},
"detected_kind": "other_address_change",
"other_address": {
"action": "added",
"purpose": "statutaire_zetel",
"address_new": "Goswin de Stassartstraat 19, 2800 Mechelen",
"address_old": null,
"effective_date": "2021-10-29",
"effective_date_is_approximate": false
},
"mandate_renewal": {
"period_end": null,
"mandate_kind": "beheerder",
"period_start": "2021-10-29",
"remuneration_eur": null,
"remuneration_kind": "gratuit",
"person_or_entity_kbo": null,
"person_or_entity_name": "Bioqube Factory Project Company CommV"
},
"subject_company": {
"kbo": "0776.938.722",
"name_full": "Temmune Therapeutics",
"legal_form": "CommV"
},
"accounts_deposit": {
"filing_kind": null,
"fiscal_year_end": "2022-12-31",
"filing_reference": null
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Laura Sellenslagh",
"org_rep_person_name": null
},
"co_filed_documents": [
"Oprichtingsakte van de vennootschap",
"Statuten van de vennootschap"
],
"fiscal_year_change": {
"new_end_mm_dd": "12-31",
"old_end_mm_dd": null,
"new_start_mm_dd": "01-01",
"old_start_mm_dd": null,
"first_full_new_year": 2022,
"transition_period_end": "2022-12-31"
},
"liquidation_closure": null,
"officer_designation": {
"role": "beheerder",
"organ": "bestuursorgaan",
"person_name": "Dirk Reyn"
},
"special_procuration": null,
"is_volet_a_only_stub": false,
"vakbekwaamheid_change": null,
"should_reroute_to_category": null,
"single_shareholder_declaration": null
}| Legal nameNL | Temmune Therapeutics |
| AbbreviationNL | TemmuneTx |